This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Cevec Pharmaceutical Gmbh. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Hanns-Martin Schmidt: Innovator in Glycoprotein Technology
Introduction
Hanns-Martin Schmidt is a notable inventor based in Cologne, Germany. He has made significant contributions to the field of biotechnology, particularly in the area of glycoproteins. His work focuses on enhancing the properties of these complex molecules, which are crucial in various biological processes.
Latest Patents
Hanns-Martin Schmidt holds a patent for "Recombinant glycoproteins with reduced antennary fucosylation." This invention relates to methods for reducing antennary fucosylation of complex N-glycans in recombinantly expressed glycoproteins. The patent also includes cell lines that can be utilized in these methods, as well as the respective recombinant glycoproteins and methods for expressing them in said cell lines. He has 1 patent to his name.
Career Highlights
Hanns-Martin Schmidt is currently associated with Cevec Pharmaceutical GmbH, a company that specializes in biopharmaceutical development. His role at the company allows him to apply his innovative ideas in a practical setting, contributing to advancements in the pharmaceutical industry.
Collaborations
Some of his notable coworkers include Markus Ribbert and Gudrun Schiedner. Their collaboration fosters a productive environment for research and development in glycoprotein technology.
Conclusion
Hanns-Martin Schmidt's work in recombinant glycoproteins represents a significant advancement in biotechnology. His innovative approaches and collaborations continue to influence the field positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile